MedTrace Logo

Assessment of the Effect of the Product RV2666C Formula LA2984 Compared to an Untreated Area With an Epidermally Ablated Skin Model Obtained With an Erbium YAG Laser on Adults Presenting IV to VI Skin Phototype

NCT07166484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2026-05-05

No results posted yet for this study

Summary

In this study, we assess the efficacy of a cosmetic product in adults with IV to VI skin phototype.

This study is conducted as a monocentric, controlled, compared with an untreated area and randomized for the area of product application.

To perform this clinical study, minimum 20 - maximum 24 subjects (man or woman), aged from 18 to 50 years are enrolled.

The subjects applied the investigational product on an area located on the anterior side of the forearm, following the laser YAG act, once a day and under occlusion from Day 1 to Day 3 included. Then it is applied twice a day in an open way from Day 4 until Day 18 included.

10 visits are planned:

* Visit 1: Inclusion visit = Day 1
* Visit 2 to Visit 5: Intermediate visits = Day 2 to Day 5
* Visit 6: Intermediate visit = Day 8
* Visit 7: Intermediate visit = Day 10
* Visit 8: Intermediate visit = Day 12
* Visit 9: Intermediate visit = Day 15
* Visit 10: End of study visit = Day 19-1

Conditions

  • Healthy

Interventions

OTHER

Cosmetic product RV2666C LA2984

The product is applied, according to randomization, on an area located on the anterior side of the forearm, following the laser YAG act, once a day and under occlusion from Day 1 to Day 3 included. Then it is applied twice a day in an open way from Day 4 until Day 18 included.

Sponsors & Collaborators

  • Pierre Fabre Dermo Cosmetique

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2025-12-05
Completion
2025-12-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166484 on ClinicalTrials.gov